Calprotectin (a major S100 leucocyte protein) predicts 10-year radiographic progression in patients with rheumatoid arthritis

Annals of the Rheumatic Diseases

Volumn 69, Issue 1, 2010, Pages 150-154

  Berner Hammer, H ^a   Odegard S ^a   Syversen, S W ^a   Landewe R ^b   Van Der Heijde, D ^a,c   Uhlig, T ^a   Mowinckel, P ^a   Kvien, T K ^a,d  

^a DIAKONHJEMMET HOSPITAL   (Norway)

^b MAASTRICHT UNIVERSITY MEDICAL CENTER   (Netherlands)

^c LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^d UNIVERSITY OF OSLO   (Norway)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL MARKER; C REACTIVE PROTEIN; CALGRANULIN; CYCLIC CITRULLINATED PEPTIDE ANTIBODY; RHEUMATOID FACTOR;

ADULT; ARTICLE; CLINICAL ASSESSMENT; DISEASE COURSE; DISEASE DURATION; DISEASE MARKER; ERYTHROCYTE SEDIMENTATION RATE; FEMALE; HAND RADIOGRAPHY; HUMAN; INFLAMMATION; JOINT DESTRUCTION; JOINT RADIOGRAPHY; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROGNOSIS; PROTEIN BLOOD LEVEL; RHEUMATOID ARTHRITIS; RHEUMATOID ARTHRITIS ARTICULAR DAMAGE SCORE; SCORING SYSTEM; SYNOVIAL FLUID; VAN DER HEIJDE MODIFIED SHARP SCORE;

ADULT; ARTHRITIS, RHEUMATOID; BIOLOGICAL MARKERS; DISEASE PROGRESSION; FEMALE; FOLLOW-UP STUDIES; HUMANS; INFLAMMATION MEDIATORS; LEUKOCYTE L1 ANTIGEN COMPLEX; MALE; MIDDLE AGED; PROGNOSIS; RHEUMATOID FACTOR; SEVERITY OF ILLNESS INDEX;

EID: 73449083779     PISSN: 00034967     EISSN: 14682060     Source Type: Journal    
DOI: 10.1136/ard.2008.103739     Document Type: Article

References (37)

1. Ødegård S, Landewé, van der Heijde D, et al. Association of early radiographic damage with impaired physical function in rheumatoid arthritis. A ten-year, longitudinal observational study in 238 patients. Arthritis Rheum 2006;54:68-75.
2. Fagerhol MK, Dale I, Andersson T. A radioimmunoassay for a granulocyte protein as a marker in studies on the turnover of such cells. Bull Eur Physiopathol Respir 1980;16(Suppl):273-81.
3. Edgeworth J, Gorman M, Bennett R, et al. Identification of p8,14 as a highly abundant heterodimeric calcium binding protein complex of myeloid cells. J Biol Chem 1991;266:7706-13.
4. Dale I, Brandtzaeg P, Fagerhol MK, et al. Distribution of a new myelomonocytic antigen (L1) in human peripheral blood leucocytes. Am J Clin Pathol 1985;84:24-34.
5. Johne B, Fagerhol MK, Lyberg T, et al. Functional and clinical aspects of the myelomonocyte protein calprotectin. J Clin Pathol: Mol Pathol 1997;50:113-23.
6. Fagerhol MK, Dale I, Andersson T. Release and quantitation of a leucocyte derived protein (L1). Scand J Haematol 1980;24:3913-8.
7. Foell D, Roth J. Proinflammatory S100 proteins in arthritis and autoimmune disease. Arthritis Rheum 2004;50:3762-71.
8. Berntzen HB, Munthe E, Fagerhol MK. A longitudinal study of the leucocyte protein L1 as an indicator of disease activity in patients with rheumatoid arthritis. J Rheumatol 1989;16:1416-20.
9. Berntzen HB, Fagerhol MK, Østensen M, et al. The L1 protein as a new indicator of inflammatory activity in patients with juvenile rheumatoid arthritis. J Rheumatol 1991;18:133-8.
10. Brun JG, Haga H-J, Bøe E, et al. Calprotectin in patients with rheumatoid arthritis: relation to clinical and laboratory variables of disease activity. J Rheumatol 1992;19:859-62.
11. Hammer HB, Kvien TK, Glennås A. A longitudinal study of calprotectin as an inflammatory marker in patients with reactive arthritis. Clin Exp Rheumatol 1995;13:59-64.
12. Frosch M, Vogl T, Seeliger S, et al. Expression of myeloid-related proteins 8 and 14 in systemic-onset juvenile rheumatoid arthritis. Arthritis Rheum 2003;48:2622-6.
13. Haga H-J, Brun JG, Berntzen HB, et al. Calprotectin in patients with systemic lupus erythematosus: relation to clinical and laboratory parameters of disease activity. Lupus 1993;2:47-50.
14. Odink K, Cerletti N, Brüggen J, et al. Two calcium-binding proteins in infiltrate macrophages of rheumatoid arthritis. Nature 1987;330:80-2.
15. Wilkinson MM, Busuttil A, Hayward C, et al. Expression pattern of two related cystic fibrosis-associated calcium-binding proteins in normal and abnormal tissues. J Cell Sci 1988;91:221-30.
16. Dorin JR, Novak M, Hill RE, et al. A clue to the basic defect in cystic fibrosis from cloning the CF antigen gene. Nature 1987;326:614-7.
17. Frosch M, Strey A, Vogl T, et al. Myeloid-related proteins 8 and 14 are specifically secreted during interaction of phagocytes and activated endothelium and are useful markers for monitoring disease activity in pauciarticular-onset juvenile rheumatoid arthritis. Arthritis Rheum 2000;43:628-37.
18. Youssef P, Roth J, Frosch M, et al. Expression of myeloid related proteins (MRP) 8 and 14 and the MRP8/14 heterodimer in rheumatoid arthritis synovial membrane. J Rheumatol 1999;26:2523-8.
19. Berntzen HB, Ölmez Ü, Fagerhol MK, et al. The leucocyte protein L1 in plasma and synovial fluid from patients with rheumatoid arthritis and osteoarthritis. Scand J Rheumatol 1991;20:74-82.
20. Uchida T, Fukawa A, Uchida M, et al. Application of a novel protein biochip technology for detection and identification of rheumatoid arthritis biomarkers in synovial fluid. J Proteome Res 2002;1:495-9.
21. Hammer HB, Ødegård S, Fagerhol MK, et al. Calprotectin (a major leucocyte protein) is strongly and independently correlated with joint inflammation and damage in rheumatoid arthritis. Ann Rheum Dis 2007;66:1093-7.
22. Arnett FC, Edworthy SM, Bloch DA, et al. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum 1988;31:315-24.
23. Smedstad LM, Moum T, Guillemin F, et al. Correlates of functional disability in early rheumatoid arthritis: a cross-sectional study of 706 patients in four European countries. Br J Rheumatol 1996;35:746-51.
24. Smedstad LM, Vaglum P, Kvien TK, et al. The relationship between self-reported pain and sociodemographic variables, anxiety, and depressive symptoms in rheumatoid arthritis. J Rheumatol 1995;22:514-20.
25. Kristinsson J, Røseth A, Fagerhol MK, et al. Fecal calprotectin concentration in patients with colorectal carcinoma. Dis Colon Rectum 1998;41:316-21.
26. Syversen SW, Gaarder PI, Goll GL, et al. High anti-cyclic citrullinated peptide levels and an algorithm of four variables predict radiographic progression in patients with rheumatoid arthritis: results from a 10-year longitudinal study. Ann Rheum Dis 2008;67:212-7.
27. Zijlstra TR, Bernelot Moens HJ, Bukhari MAS. The rheumatoid arthritis articular damage score: first steps in developing a clinical index of long term damage in RA. Ann Rheum Dis 2002;61:20-3.
28. Van der Heijde DM, van Riel PL, Nuver-Zwart IH, et al. Effects of hydroxychloroquine and sulphasalazine on progression of joint damage in rheumatoid arthritis. Lancet 1989;1:1036-8.
29. van der Heijde D. How to read radiographs according to the Sharp/van der Heijde method. J Rheumatol 2000;27:261-3.
30. Liao H, Wu J, Kuhn E, et al. Use of mass spectrometry to identify protein biomarkers of disease severity in the synovial fluid and serum of patients with rheumatoid arthritis. Arthritis Rheum 2004;50:3792-803.
31. Madland TM, Hordvik M, Haga H-J, et al. leucocyte protein calprotectin and outcome in rheumatoid arthritis. Scand J Rheumatol 2002;31:351-4.
32. Van Zeben D, Hazes JMW, Zwinderman AH, et al. Clinical significance of rheumatoid factors in early rheumatoid arthritis: results of a follow up study. Ann Rheum Dis 1992;51:1029-35.
33. Bongi SM, Manetti R, Melchiorre D, et al. Anti-cyclic citrullinated peptide antibodies are highly associated with severe bone lesions in rheumatoid arthritis. Autoimmunity 2004;37:495-501.
34. Hammer HB, Haavardsholm EA, Kvien TK. Calprotectin (a major leucocyte protein) is associated with the levels of anti-CCP and rheumatoid factor in a longitudinal study of patients with very early rheumatoid arthritis. Scand J Rheumatol 2008;37:179-82.
35. Berntzen HB, Munthe E, Fagerhol MK. The major leucocyte protein L1 as an indicator of inflammatory joint disease. Scand J Rheumatol Suppl 1988;76:251-6.
36. Brun JG, Madland TM, Gran JT, et al. A longitudinal study of calprotectin in patients with polymyalgia rheumatica or temporal arteritis: relation to disease activity. Scand J Rheumatol 2005;34:125-8.
37. Maksymowych WP, Landewe R, Boers M, et al. Development of draft validation criteria for a soluble biomarker to be regarded as a valid biomarker reflecting structural damage endpoints in rheumatoid arthritis and spondyloarthritis clinical trials. J Rheumatol 2007;34:634-40.